Understand the source comparison
Peptides for Low Testosterone: What Research Shows vs What Marketing Claims
Comparison table introducing three common peptide classes, their mechanisms, evidence base, and typical research dosing. Kisspeptin Analogs Stimulates GnRH neurons in the hypothalamus to increase pulsatile GnRH release Phase 1–2 trials show 3–4× increase in LH
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Comparison table introducing three common peptide classes, their mechanisms, evidence base, and typical research dosing.
- Kisspeptin Analogs
- Stimulates GnRH neurons in the hypothalamus to increase pulsatile GnRH release
- Phase 1–2 trials show 3–4× increase in LH within 60 minutes; testosterone elevation sustained 8–12 hours
- 1–10 nmol/kg (kisspeptin-10) per infusion in clinical studies
- Most upstream intervention. Restores hypothalamic signaling in secondary hypogonadism
- Gonadorelin (GnRH)
- Mimics endogenous GnRH; binds to pituitary receptors to trigger LH and FSH secretion
- FDA-approved for diagnostic testing; pulsatile protocols restore testosterone to 450–650 ng/dL in hypothalamic hypogonadism
- 25–100 mcg per pulse every 90–120 minutes via pump
- Requires pulsatile administration. Continuous dosing suppresses pituitary
- hCG (Human Chorionic Gonadotropin)
- Mimics LH; binds to Leydig cell receptors to stimulate testosterone synthesis and prevent testicular atrophy
- Decades of clinical use in fertility and TRT adjunct; maintains intratesticular testosterone >100 ng/mL
- 250–500 IU 2–3× weekly
- Most direct Leydig cell stimulation. Preserves testicular function during TRT